ArticleEuropean radiology2018
Amide proton transfer imaging for differentiation of benign and atypical meningiomas.
Article in European radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- An evidence-based approach to evaluate the accuracy of amide proton transfer-weighted MRI in characterization of gliomas.Medicine · 2019Pooled it
- A Machine Learning Model Based on Unsupervised Clustering Multihabitat to Predict the Pathological Grading of Meningiomas.BioMed research international · 2022Trial
- Grading of glioma and prediction of IDH mutation status via longitudinal relaxation time in rotating frame mapping on 5-T magnetic resonance imaging: added value to amide proton transfer-weighted imaging.Quantitative imaging in medicine and surgery · 2026Article
- Diagnostic performance of amide proton transfer-weighted imaging and four advanced diffusion-weighted MRI models for meningioma grading and subtyping.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- 3-Tesla amide proton transfer-weighted imaging (APT-WI): elevated signal also in tumor mimics.European radiology · 2025Article
- Preclinical monitoring of radiation-induced brain injury via GluCEST MRI and resting-state fMRI at 7 T: an exploratory study on MRI-guided OAR avoidance.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Article
- Improved brain tumor diagnostics and follow-up with novel magnetic resonance imaging methods: A single center study protocol.PloS one · 2025Article
- A case of atypical meningioma presenting spontaneous infarction: the findings of magnetic resonance imaging, including amide proton transfer-chemical exchange saturation transfer imaging.BJR case reports · 2024Article
- Evolving concepts in margin strategies and adaptive radiotherapy for glioblastoma: A new future is on the horizon.Neuro-oncology · 2024Review
- Image quality assessment and feasibility of three-dimensional amide proton transfer-weighted imaging for hepatocellular carcinoma.Quantitative imaging in medicine and surgery · 2024Article
- Biogenic Imaging Contrast Agents.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Whole-tumor amide proton transfer-weighted imaging histogram analysis to predict pathological extramural venous invasion in rectal adenocarcinoma: a preliminary study.European radiology · 2023Article
- Amide Proton Transfer-Chemical Exchange Saturation Transfer Imaging of Intracranial Brain Tumors and Tumor-like Lesions: Our Experience and a Review.Diagnostics (Basel, Switzerland) · 2023Review
- Quantitative Chemical Exchange Saturation Transfer Imaging of Amide Proton Transfer Differentiates between Cerebellopontine Angle Schwannoma and Meningioma: Preliminary Results.International journal of molecular sciences · 2022Article
- Investigation of breast cancer microstructure and microvasculature from time-dependent DWI and CEST in correlation with histological biomarkers.Scientific reports · 2022Article
- Molecular Imaging of Brain Tumors and Drug Delivery Using CEST MRI: Promises and Challenges.Pharmaceutics · 2022Review
- The Value of APTw CEST MRI in Routine Clinical Assessment of Human Brain Tumor Patients at 3T.Diagnostics (Basel, Switzerland) · 2022Article
- Differentiation of Meningiomas and Gliomas by Amide Proton Transfer Imaging: A Preliminary Study of Brain Tumour Infiltration.Frontiers in oncology · 2022Article
- 3D Amide Proton Transfer Weighted Brain Tumor Imaging With Compressed SENSE: Effects of Different Acceleration Factors.Frontiers in neuroscience · 2022Article
- Predicting the grade of meningiomas by clinical-radiological features: A comparison of precontrast and postcontrast MRI.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
purposeTo investigate the difference in amide proton transfer (APT)-weighted signals between benign and atypical meningiomas and determine the value of APT imaging for differentiating the two.
methodsFifty-seven patients with pathologically diagnosed meningiomas (benign, 44; atypical, 13), who underwent preoperative MRI with APT imaging between December 2014 and August 2016 were included. We compared normalised magnetisation transfer ratio asymmetry (nMTR
resultsThe nMTR
conclusionAtypical meningiomas exhibited significantly higher APT-weighted signal intensities than benign meningiomas. The discriminative value of conventional MRI improved significantly when combined with APT imaging for diagnosis of atypical meningioma. KEY POINTS: • APT imaging is useful for differentiating between atypical and benign meningiomas. • Atypical meningiomas exhibited high APT-weighted signal intensity than benign meningiomas. • The diagnostic performance of MRI improved with nMTR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.